Please login to the form below
everolimus
This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
Pfizer and Arvinas are also planning to initiate two additional trials of ARV-471 this year, including a second phase 1b combination trial with cancer growth blocker everolimus, as well as
Latest news
-
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
Novartis’ Afinitor (everolimus) versus Sutent (sunitinib) for the first-line treatment of advanced RCC patients.
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
In addition to the positive results for the Keytruda plus Lenvima combination, Merck and Eisai added that Lenvima plus everolimus also showed improvements in PFS and ORR compared to Sutent. ... However, Lenvima plus everolimus did not demonstrate an
-
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
In a separate arm of the KEYNOTE-581 trial, the partner companies also evaluated Lenvima plus Novartis’ Afinitor (everolimus) in advanced RCC, with this combination also topping Sutent on PFS and
-
BMS unveils long-term results for Opdivo in kidney cancer
alive at this time-point compared to 18% of those treated only with the standard chemotherapy drug everolimus.
-
NICE nod for Lilly’s breast cancer drug Verzenio via CDF
NICE notes in its guidance that Verzenio and fulvestrant will be an option “where exemestane plus everolimus would be the most appropriate alternative treatment.”. ... On that point, Baroness Morgan said that as everolimus with exemestane is
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
BMS unveils long-term results for Opdivo in kidney cancer
NICE nod for Lilly’s breast cancer drug Verzenio via CDF
More from news
Approximately 8 fully matching, plus 68 partially matching documents found.
Latest from PMHub
-
Oncology drugs under AMNOG
patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- US demand for COVID-19 antibody treatments rising fast
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- EU “still interested” in Valneva COVID vaccine despite UK snub
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Advancing Drug Discovery with Structured and Intelligent Data
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Ashfield Health announces three new senior hires
- Future of MHRA uncertain amid Brexit-fuelled shake up
PMHub
TRIDUCIVE
Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
